18 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Optimization of allosteric MEK inhibitors. Part 2: Taming the sulfamide group balances compound distribution properties.

Bayer Healthcare
Neutrophil elastase inhibitors for the treatment of (cardio)pulmonary diseases: Into clinical testing with pre-adaptive pharmacophores.

Bayer Healthcare
Radiofluorinated derivatives of 2-(phosphonomethyl)pentanedioic acid as inhibitors of prostate specific membrane antigen (PSMA) for the imaging of prostate cancer.

Bayer Healthcare
Novel tetrahydrochinoline derived CETP inhibitors.

Bayer Healthcare
Pochonins A-F, new antiviral and antiparasitic resorcylic acid lactones from Pochonia chlamydosporia var. catenulata.

Bayer Healthcare
Biphenyls as potent vitronectin receptor antagonists. Part 3: Squaric acid amides.

Bayer Healthcare
Optimization of imidazole amide derivatives as cannabinoid-1 receptor antagonists for the treatment of obesity.

Bayer Healthcare
Constrained analogs of CB-1 antagonists: 1,5,6,7-Tetrahydro-4H-pyrrolo[3,2-c]pyridine-4-one derivatives.

Bayer Healthcare
Novel, selective indole-based ECE inhibitors: lead optimization via solid-phase and classical synthesis.

Bayer Healthcare
Comparison of different heterocyclic scaffolds as substrate analog PDE5 inhibitors.

Bayer Healthcare
Novel heterocyclic thyromimetics.

Bayer Healthcare
Optimization of allosteric MEK inhibitors. Part 1: Venturing into underexplored SAR territories.

Bayer Healthcare
Novel heterocyclic thyromimetics. Part 2.

Bayer Healthcare
Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors

Forma Tm2
Benzoxazines, benzothiazines, and related compounds having NOS inhibitory activity

Neuraxon
Tyrphostins IV--highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines.

Hebrew University of Jerusalem